RESEARCH Open Access

Outcomes of delayed versus early endoscopic intervention for acute biliary pancreatitis with non-severe acute cholangitis

Yunxiao Lyu^{1*}, Shenjian Ye^{1,2} and Bin Wang¹

Abstract

Background: Despite previous studies on endoscopic interventions in patients with acute biliary pancreatitis (ABP), the optimal time to perform endoscopic retrograde cholangiopancreatography (ERCP) for ABP with non-severe acute cholangitis (AC) remains controversial.

Methods: We performed a retrospective cohort analysis of patients with concurrent ABP and non-severe AC. The patients were divided into two groups: those who underwent ERCP \leq 72 h after admission (early ERCP group) and those who underwent ERCP > 72 h after admission (delayed ERCP group). The primary outcomes were the technical success rate and ERCP-related complications.

Results: The study involved 164 patients (early ERCP, n = 70; delayed ERCP, n = 94) who were treated from 1 December 2 to 2016 to 12 December 2021. The patients' baseline characteristics were not significantly different between the two groups. The technical success rate of ERCP was similar between the two groups (94.29% vs. 97.87%, p = 0.43). Morbidity was also similar between the two groups (p = 0.83). There was no significant difference in the total hospital stay (p = 0.13). However, the early ERCP group had a longer post-ERCP hospital stay (p < 0.001).

Conclusion: This retrospective analysis showed that delayed ERCP performed > 72 h after admission has economic and safety outcomes similar to those of early ERCP for patients with concurrent ABP and non-severe AC.

Keywords: Endoscopic retrograde cholangiopancreatography, Acute biliary pancreatitis, Acute cholangitis

Introduction

Acute biliary pancreatitis (ABP) is thought to occur secondary to biliary obstruction, which is most frequently caused by bile duct stones [1]. ABP is one of the most prevalent digestive tract diseases in clinical practice, leading to a tremendous financial burden in human society. ABP often occurs in conjunction with acute cholangitis (AC). Endoscopists frequently perform endoscopic

retrograde cholangiopancreatography (ERCP) for the treatment of ABP. Several studies have been conducted on this topic. Previous studies have demonstrated that early ERCP may be beneficial for ABP with severe cholangitis [2, 3]. However, the optimal time of performing ERCP for patients with ABP remains controversial [4, 5]. Several previous studies and guidelines have indicated that for patients with ABP, ERCP should be performed early (within 72 h) in patients without cholangitis and more urgently in patients with AC [5–7]. However, most cases of ABP are self-limiting, and up to 15% of stones may pass spontaneously during the early period of ABP [8]. Despite these previous studies and guidelines, the optimal time of performing ERCP for the treatment of

¹ Department of Hepatobiliary Surgery, Dongyang People's Hospital, Affiliated Dongyang Hospital of Wenzhou Medical University, 60 West Wuning Road, Dongyang 322100, Zhejiang, People's Republic of China Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and you rintended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativeccommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

^{*}Correspondence: lvyunxiao1986@gmail.com

Lyu et al. BMC Surgery (2022) 22:440 Page 2 of 6

ABP with non-severe AC remains controversial because of the ambiguous definitions of the timing of ERCP and cholangitis. We conducted a retrospective analysis to investigate the outcomes of early ERCP (\leq 72 h after admission) and delayed ERCP (>72 h after admission) for treatment of ABP with non-severe AC.

Materials and methods

Patients

We retrospectively analyzed patients diagnosed as ABP with non-severe AC due to common bile duct stones from 1 to 2016 to 12 December 2021 using the electronic medical database of our hospital. The study was approved by the ethics committee of Dongyang People's Hospital. AP was defined according to the American College of Gastroenterology guidelines: (1) abdominal pain consistent with the disease, (2) serum amylase and/or lipase greater than three times the upper limit of normal, and/ or (3) characteristic findings from abdominal imaging, as well as abnormal liver enzymes[4]. Biliary pancreatitis was defined at least one of the following criteria: (1) gallstones or biliary sludge on imaging; (2) dilated CBD on imaging; (3) total bilirubin more than two times the upper limit of normal. The severity of ABP was determined according to the Bedside Index of Severity in Acute Pancreatitis (BISAP) score [9]. The definition and severity of acute cholangitis were determined according to the 2018 Tokyo Guidelines [10]. ERCP-related complications were assessed based on the American Society for Gastrointestinal Endoscopy guidelines [11]. All medical information was recorded in an electronic system. Data regarding age, sex, body mass index, comorbidities, American Society of Anesthesiologists (ASA) physical status, and laboratory findings were collected. Patients were excluded if they had not undergone ERCP or if they had undergone digestive tract reconstruction. Patients with obstruction without AC or AC due to stricture, tumor, stent were also excluded. The included patients were divided into two groups according the time at which ERCP was performed after admission: those who underwent ERCP ≤ 72 h after admission (early ERCP group) and those who underwent ERCP>72 h after admission (delayed ERCP group). All patients received intravenous fluids and antibiotic treatment once acute cholangitis had been diagnosed.

ERCP procedures

All ERCP procedures were performed by two expert endoscopists who had performed 200 ERCP per year with a standard therapeutic duodenoscope (Olympus JF-260; Olympus, Tokyo, Japan). All patients received topical pharyngeal anesthesia with 2% lidocaine followed by intravenous administration of midazolam for sedation

and fentanyl for analgesia; the doses used were at the discretion of the endoscopist. Cannulation of the common bile duct was attempted with a conventional cannula with a guidewire. All patients were monitored continuously during the procedure by measurement of blood pressure, heart rate, respiratory rate, and arterial oxygen saturation.

Outcome measures

The primary outcomes were the technical success rate and ERCP-related complications. The secondary outcomes were the hospital stay and patient cost. Technical success was defined as successful biliary cannulation and removal of stones from the bile duct. ERCP-related complications were defined according to the American Society for Gastrointestinal Endoscopy guidelines [11].

Statistical analysis

Statistical analyses of the clinical data were performed using SPSS software version 26 (IBM Corp., Armonk, NY, USA). Nonparametric variables were analyzed with the Mann–Whitney U test, and categorical-type outcomes were analyzed with the chi-square test or Fisher's exact test. A p value of < 0.05 was considered statistically significant. All authors had access to the study data and reviewed and approved the final article.

Results


Baseline characteristics

In total, 164 patients were enrolled in our study (Fig. 1). The early ERCP group comprised 70 patients (39 men, 31 women), and the delayed ERCP group comprised 94 patients (42 men, 52 women). The patients' mean age was 62.51 ± 14.38 years in the early ERCP group and 64.88 ± 16.00 years in the delayed ERCP group. The mean time from admission to ERCP was 44.07 ± 20.53 h in the early ERCP group and 163.83 ± 65.60 h in the delayed ERCP group. There was no significant difference in the amylase concentration, lipase concentration, or BISAP score between the two groups. The patients' demographics and clinical characteristics are listed in Table 1. There were no significant differences in age, sex, ASA physical status, or laboratory data between the two groups.

Primary outcome and ERCP-related complications during waiting time

Primary outcome and ERCP-related measures were showed in Table 2. Technical success was achieved in 66 (94.29%) and 92 (97.87%) patients in the early and delayed ERCP groups, respectively ($p\!=\!0.43$). Endoscopic sphincterotomy, endoscopic papillary balloon dilatation, and both were performed in 30, 25, and 11 patients, respectively, in the early ERCP group and in 36, 29, and 27

Lyu et al. BMC Surgery (2022) 22:440 Page 3 of 6



patients, respectively in the delayed ERCP group. There was no significant difference in the amylase or lipase concentration 24 h after ERCP between the two groups (p=0.40 and p=0.12, respectively). In the early ERCP group, four patients developed ERCP-related pancreatitis, one developed bleeding, and one developed cholangitis. In the delayed ERCP group, seven patients developed ERCP-related pancreatitis, one developed cholecystitis, and one developed cholangitis. There was no significant difference in these post-ERCP complications. No mortality occurred in either group. Laparoscopic cholecystectomy was performed after ERCP in 22 patients in the early ERCP group and 32 patients in the delayed ERCP group. There was no significant difference in the total hospital stay (12.76 \pm 9.33 vs. 13.48 \pm 4.53 days, p = 0.13). However, the length of hospital stay after ERCP was shorter in the delayed than early ERCP group (6.59 ± 3.37) vs. 10.94 ± 9.43 days, respectively; p = 0.00). There was no significant difference in patient cost between the two groups $(24993.06 \pm 9503.63 \text{ vs. } 29547.13 \pm 6815.92,$ p = 0.15).

Discussion

In this present study, we conducted a retrospective analysis to examine the clinical outcomes of different times to endoscopic intervention for ABP with non-severe cholangitis. Our study showed delayed ERCP performed > 72 h after admission has economic and safety outcomes similar to those of early ERCP for patients with concurrent ABP and non-severe cholangitis.

Performance of early ERCP is supported by the fact that the occurrence of biliary pancreatitis is often accompanied by the appearance of cholangitis. Early removal of the bile duct obstruction can reduce the reflux of pancreatic fluid and severity of pancreatitis. A guideline published in 2013 recommended the performance of ERCP within 24 h after admission for treatment of cholangitis in patients with ABP. However, the level of evidence was low. Additionally, some of the stones that caused ABP passed spontaneously into the duodenum, and most cases of ABP were self-limiting [12]. Moreover, early pancreatitis may cause duodenal edema, which may increase the difficulty of ERCP. Our study showed that delayed ERCP for ABP with non-severe AC had a technical success rate and safety outcome similar to those of early ERCP. However, early group has more difficulty cannulation than delayed. This may be related to factors such as duodenal papilla edema in the early stages of pancreatitis. Although there was no difference in the success rate of ERCP or incidence of postoperative complications between early and delayed ERCP, the early ERCP group did not gain an advantage in the length of hospital stay. Delayed ERCP can give patients more time to complete various examinations and, in some cases, can avoid unnecessary ERCP. In the early period of ABP, abdominal ultrasound has a low sensitivity for common bile duct [13]. Previous studies have confirmed the clinical value of Endoscopic ultrasound in the diagnosis of common bile duct stones [14]. Compared with abdominal ultrasound, EUS has higher specificity and sensitivity, and can detect Lyu et al. BMC Surgery (2022) 22:440 Page 4 of 6

Table 1 Characteristics of the patients at baseline

Characteristic	Group I (N=70)	Group II (N = 94)	<i>p</i> -value
Age (years)	62.51 ± 14.38	64.88 ± 16.00	0.33
Male/female, N (%)	39/31	42/52	0.21
Time of from admission to ERCP (hour)	44.07 ± 20.53	163.83 ± 65.60	0.00
Temperature (°C)	36.86 ± 0.59	37.01 ± 0.82	0.11
Total bilirubin (umol/L)	56.44 ± 48.02	41.63 ± 34.99	0.09
Direct bilirubin (umol/L)	39.14 ± 38.64	27.34 ± 28.84	0.09
BMI (kg/m ²)	23.30 ± 2.17	23.38 ± 2.55	0.81
CRP (mg/L)	29.46 ± 44.33	24.38 ± 33.47	0.43
WBC (U/L)	11.01 ± 4.51	11.29 ± 4.18	0.18
PLT (U/L)	215.10 ± 71.90	199.60 ± 65.68	0.09
Amylase (U/L)	1534.13 ± 1502.45	1653.84 ± 1564.03	0.38
Creatine (U/L)	70.62 ± 21.21	70.00 ± 33.61	0.99
ALT (U/L)	220.11 ± 191.51	230.47 ± 219.35	0.73
AST U/L)	245.53 ± 217.38	236.31 ± 260.62	0.86
ALP (U/L)	176.17 ± 133.10	167.95 ± 136.14	0.74
γ-GT (U/L)	324.02 ± 246.87	391.3 ± 326.18	0.18
BISAP	1.02 ± 0.83	1.09 ± 0.86	0.72
Severity of AC			0.86
Mild	52	71	
Moderate	18	23	
Lipase (U/L)	605.03 ± 537.73	452.51 ± 395.14	0.26
Combines comorbid, N (%)			
Cardiovascular disease	28 (40)	35 (37.23)	0.72
Diabetes mellitus	10 (14.29)	11 (11.70)	0.62
COPD	3 (4.29)	3 (3.19)	0.71
MT	7 (10)	3 (3.19)	0.07
Others	1 (1.43)	3 (3.19	0.47
ASA(I/II/III/IV)	10/42/17/1	12/61/21/0	0.65
Previous abdominal surgery, N (%)	18(25.71)	14 (14.89)	0.08
Previous cholecystectomy, N (%)	9 (12.86)	5 (5.32)	0.09
Previous ERCP, N (%)	2 (2.86)	2 (2.13)	0.76

Continuous data were showed as mean \pm SD

ERCP endoscopic retrograde cholangiopancreatography; COPD chronic obstructive pulmonary disease; MT malignant tumor; BMI body mass index; ALP alkaline phosphatase; r-GT γ-glutamyl transferase; AST aspartate aminotransferase; ALT alanine aminotransferase; WBC white blood cell; CRP C-reactive protein; TB total bilirubin; DB direct bilirubin; BISAP bedside index for severity in acute pancrieatitis

some bile duct stones that cannot be detected by other tests. In this study, this part of the data is lacking because EUS is currently less performed in our hospital. Delayed ERCP did not increase the hospital stay or cost in this study. In clinical practice, the cost-effectiveness of ERCP for treatment of ABP must also be considered.

The time point adopted in our study was 72 h after admission. The time point varied among previous studies (admission or onset of symptoms). We believe that early acute pancreatitis is sometimes difficult to distinguish from acute cholangitis in the early stage. Many patients have difficulty accurately recalling the onset of their

symptoms. Therefore, we believe that it is reasonable and feasible to adopt the time after admission.

Fölsch et al. [15] demonstrated that early ERCP is not superior to delayed ERCP for ABP without cholangitis. In the present study, acute cholangitis was defined according to the 2018 Tokyo guideline, which classifies acute cholangitis as mild, moderate, and severe [10]. According to the Tokyo guideline, urgent ERCP should be performed for severe cholangitis. For mild and moderate cholangitis, several studies have demonstrated that early ERCP and selective ERCP produced similar outcomes in terms of mortality and morbidity [16, 17]. In our study,

Lyu et al. BMC Surgery (2022) 22:440 Page 5 of 6

Table 2 Primary outcome and ERCP-related measures

	Group I (n = 70)	Group II (n = 94)	<i>p</i> -value
Diameter of CBD (cm),	1.11±0.95	1.13±0.89	0.89
Cannulation success rate, N (%)	68(97.14)	92(97.87)	0.83
Technical success rate, N (%)	66 (94.29)	92(97.87)	0.43
Advanced cannulation techniques, N (%)	24(34.29)	16(17.02)	0.01
ERCP procedure, N (%)			0.18
EST	30 (42.86)	36 (38.30)	
EPBD	25 (35.71)	29 (30.85)	
EST + EPBD	11(15.71)	27 (28.72)	
Size of stone (mm)	10.25 ± 3.54	10.02 ± 2.71	0.49
Amylase(U/L) ^a	250.09 ± 408.12	200.20 ± 321.29	0.40
Lipase(U/L) ^a	166.25 ± 201.10	166.11 ± 199.52	0.12
Post-ERCP complications, N (%)	6 (8.57)	9 (9.57)	0.83
ERCP-related pancreatitis	4 (5.71)	7 (7.45)	0.90
Bleeding	1 (1.43)	0 (0)	0.43
Perforation	0 (0)	0 (0)	
Cholangitis	1 (1.43)	1 (1.06)	1.00
Cholecystitis	0 (0)	1 (1.06)	1.00
Mortality, N(%)	0 (0)	0 (0)	
LC after the ERCP, N(%)	22 (31.43)	32 (34.04)	0.72
Total length of hospital stays (day) ^b	12.76 ± 9.33	13.48 ± 4.53	0.13
Length of hospital stay after ERCP (day) ^b	10.94 ± 9.43	6.59 ± 3.37	0.00
Cost on the ERCP (¥)	12172.10 ± 4133.55	12435.38 ± 4178.54	0.33
Total hospital cost (¥) ^b	24993.06 ± 9503.63	29547.13 ± 6815.92	0.15

Continuous data were showed as mean \pm SD

CBD conmen bile duct; EST endoscopic sphincterotomy; EPBD endoscopic papillary balloon dilatation

most patients had non-severe cholangitis. Delayed ERCP did not increase the total hospital stay. Therefore, we believe that in the treatment of ABP with non-severe cholangitis, delayed ERCP does not increase the complication rate or length of hospital stay. Notably, there is a lack of clear diagnostic criteria for AC in ABP. We use the Tokyo guideline criteria, which have indicators regarding systemic inflammation that can be equally elevated in pancreatitis. This may pose some diagnostic difficulties. However, in combination with cholestasis and imaging evidence, it is still possible to make the diagnosis of acute cholangitis. Similarly, although previous studies have clearly defined post-ERCP complications, some of these descriptions remain ambiguous.

To the best of our knowledge, this study had the largest sample size to date, which is also one of the strengths of this research. However, this study also had two main limitations. First, it was a retrospective study, which may have led to selection bias. Additional high-quality studies

are therefore required. Second, despite being the largest sample to date, our study sample was still relatively small.

In conclusion, this retrospective analysis showed that delayed ERCP performed>72 h after admission has economic and safety outcomes similar to those of early ERCP for treatment of ABP with non-severe cholangitis.

Abbreviations

ABP: Acute biliary pancreatitis; ERCP: Endoscopic retrograde cholangiopancreatography; BISA: Bedside index of severity in acute pancreatitis.

Acknowledgements

We thank Angela Morben, DVM, ELS, from Liwen Bianji (Edanz) (www.liwen bianji.cn) for editing the English text of a draft of this manuscript.

Disclosures

Yunxiao Lyu, Bin Wang and Shenjian Ye have no conflicts of interest or financial ties to disclose.

Author contributions

YXL and BW participated in the design of the study, interpretation of data, analysis, and drafting the article. YXL and SJY collected data. All authors read and approved the final manuscript.

^a 24 h post-ERCP

^b The patients with LC were excluded

Lyu et al. BMC Surgery (2022) 22:440 Page 6 of 6

Funding

Supported by the Scientific and Technological research project of JinHua, China. No. 2021-4-142.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. This study was approved by the Ethics Committee of Dongyang People's Hospital. Written informed consent was obtained from all the participants included in the study. Informed consent was obtained from the participant included in the study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Hepatobiliary Surgery, Dongyang People's Hospital, Affiliated Dongyang Hospital of Wenzhou Medical University, 60 West Wuning Road, Dongyang 322100, Zhejiang, People's Republic of China. ²School of Medicine, Shaoxing University, Shaoxing 312000, Zhejiang, People's Republic of China.

Received: 5 July 2022 Accepted: 19 December 2022 Published online: 26 December 2022

References

- Frakes JT. Biliary pancreatitis: a review. Emphasizing appropriate endoscopic intervention. J Clin Gastroenterol. 1999;28(2):97–109.
- van Santvoort HC, Besselink MG, de Vries AC, Boermeester MA, Fischer K, Bollen TL, Cirkel GA, Schaapherder AF, Nieuwenhuijs VB, van Goor H, et al. Early endoscopic retrograde cholangiopancreatography in predicted severe acute biliary pancreatitis: a prospective multicenter study. Ann Surg. 2009;250(1):68–75.
- Chen P, Hu B, Wang C, Kang Y, Jin X, Tang C. Pilot study of urgent endoscopic intervention without fluoroscopy on patients with severe acute biliary pancreatitis in the intensive care unit. Pancreas. 2010;39(3):398–402.
- Tenner S, Baillie J, Witt J, DeVege SS. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108(9):1400–15.
- Besselink M, van Santvoort H, Freeman M, Gardner T, Mayerle J, Vege SS, Werner J, Banks P, McKay C, Fernandez-del Castillo C, French J. IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology. 2013;13(4 Suppl 2):e1-15.
- Crockett SD, Wani S, Gardner TB, Falck-Ytter Y, Barkun AN. American Gastroenterological association institute guideline on initial management of acute pancreatitis. Gastroenterology. 2018;154(4):1096–101.
- Parikh MP, Wadhwa V, Thota PN, Lopez R, Sanaka MR. Outcomes associated with timing of ERCP in acute cholangitis secondary to choledocholithiasis. J Clin Gastroenterol. 2018;52(10):e97-102.
- Cavdar F, Yildar M, Tellioğlu G, Kara M, Tilki M, Titiz M. Controversial issues in biliary pancreatitis: when should we perform MRCP and ERCP? Pancreatology. 2014;14(5):411–4.
- Wu BU, Johannes RS, Sun X, Tabak Y, Conwell DL, Banks PA. The early prediction of mortality in acute pancreatitis: a large population-based study. Gut. 2008;57(12):1698–703.
- Kiriyama S, Kozaka K, Takada T, Strasberg SM, Pitt HA, Gabata T, Hata J, Liau KH, Miura F, Horiguchi A, et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci. 2018;25(1):17–30.

- Chandrasekhara V, Khashab MA, Muthusamy VR, Acosta RD, Agrawal D, Bruining DH, Eloubeidi MA, Fanelli RD, Faulx AL, Gurudu SR, et al. Adverse events associated with ERCP. Gastrointest Endosc. 2017;85(1):32–47.
- 12. Acosta JM, Ledesma CL. Gallstone migration as a cause of acute pancreatitis. N Engl J Med. 1974;290(9):484–7.
- 13. Ammori BJ, Boreham B, Lewis P, Roberts SA. The biochemical detection of biliary etiology of acute pancreatitis on admission: a revisit in the modern era of biliary imaging. Pancreas. 2003;26(2):e32-5.
- Giljaca V, Gurusamy KS, Takwoingi Y, Higgie D, Poropat G, Štimac D, Davidson BR. Endoscopic ultrasound versus magnetic resonance cholangiopancreatography for common bile duct stones. Cochrane Database Syst Rev. 2015;2015(2):Cd011549.
- Fölsch UR, Nitsche R, Lüdtke R, Hilgers RA, Creutzfeldt W. Early ERCP and papillotomy compared with conservative treatment for acute biliary pancreatitis. The german study group on acute biliary pancreatitis. N Engl J Med. 1997;336(4):237–42.
- 16. Boey JH, Way LW. Acute cholangitis. Ann Surg. 1980;191(3):264-70.
- Miura F, Takada T, Kawarada Y, Nimura Y, Wada K, Hirota M, Nagino M, Tsuyuguchi T, Mayumi T, Yoshida M, et al. Flowcharts for the diagnosis and treatment of acute cholangitis and cholecystitis: Tokyo guidelines. J Hepatobiliary Pancreat Surg. 2007;14(1):27–34.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- $\bullet\,$ thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

